A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
Clinical trial NCT06452771 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06452771
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-27
- Primary completion
- 2026-12-04
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.